RxDoctor Payments Data

Anne Wynn, MD

Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1134462666

Payments from drug & device makers

$1,303in general payments, 2019–2025

Across 39 payments — averaging $33.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$244
  • Novo Nordisk$153
  • Sequel Med Tech, LLC$147
  • Insulet Corporation$141
  • Xeris Pharmaceuticals, Inc.$111
  • Abbott$100
  • plus $407 from 10 others

What the payments were for

  • Food & beverage$1,20392%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,303 in reported general payments places this provider in the 30th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee

Medicare billing

Part B allowed, 2024
$11,843
Medicare patients
84
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide292$351,073
JardianceEmpagliflozin178$242,585
MounjaroTirzepatide186$212,780
RybelsusSemaglutide25$46,869
TrulicityDulaglutide30$46,567
FarxigaDapagliflozin Propanediol28$38,473
JanuviaSitagliptin Phosphate39$34,367
ProliaDenosumab16$25,091
Lantus SolostarInsulin Glargine,hum.Rec.Anlog117$18,003
Humalog Kwikpen U-100Insulin Lispro48$17,176
Tresiba Flextouch U-100Insulin Degludec13$13,035
Cinacalcet Hcl22$12,798
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$9,024
Novolog FlexpenInsulin Aspart39$6,994
Sure Comfort Pen NeedlePen Needle, Diabetic37$4,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$153$397,942317 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$17$263,882237 claims
AbbVieSynthroid$65$99314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

Other endocrinology, diabetes & metabolism in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →